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In this review, we make the case that currently available ﬁgures used to deﬁne the global burden of acute
rheumatic fever and rheumatic heart disease, although crucial to control efforts, are imperfect. Data have been
hindered by methodological differences between studies, by patchy coverage within countries and across
regions, and by an incomplete understanding of the relationship between echocardiographic detection of
asymptomatic mild disease and progression to symptomatic disease. We argue that in order to advocate
effectively for patients with rheumatic heart disease now and into the future, true burden of disease estimates
on local, national, and international levels are urgently required. We critically review previous burden of
disease estimates and outline the issues in deﬁning the “true” burden of rheumatic heart disease, and we
propose a new model for rheumatic heart disease epidemiologic studies. This is of particular relevance in
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CC BY-NC-ND license.Acute rheumatic fever (ARF) and its sequel rheu-
matic heart disease (RHD) continue to cause signiﬁcant
morbidity and mortality in developing countries and
have been under-recognized as a global health problem
for decades. There are a number of reasons for this
under-recognition: the competing heavy burden of in-
fectious disease mortality in young children due to the
human immunodeﬁciency virus, malaria, tuberculosis,
diarrheal disease and pneumonia; the impressive decline
in the incidence of ARF in industrialized countries over
the second half of the last century such that ARF/RHD
are uncommon in these countries today and no longer
priority diseases; and the paucity of good quality, widely
collected epidemiologic data from developing countries
[1]. However, more recently, there is increasing aware-
ness of RHD because of prioritization of control of the
disease by a number of individual countries with high
disease burdens, reinvigorated regional initiatives directed
at control of RHD, particularly in the Paciﬁc and Africa,
and advocacy efforts led by international bodies such as
the World Heart Federation. Central to this increased
awareness have been updated and persuasive global
morbidity and mortality ﬁgures [2e4]. Recent directives
from the World Health Organization and the World
Heart Federation have pledged to decrease the number
of deaths due to noncommunicable diseases by 25% by
2025 [5]. RHD is a disease where this may be achievable
because there are relatively inexpensive, proven, and
effective control strategies that can lead to reductions in
deaths, especially in young people [6].GLOBAL HEART, VOL. 8, NO. 3, 2013
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POPULATION-BASED STUDIES
World Health Organization’s global burden of
group A streptococcal disease study
In 2005, a summary report on the global burden of group
A streptococcal disease, commissioned by the World
Health Organization, was released that encapsulated
population-based data relating to ARF and RHD published
between 1985 and 2005 [4]. This study calculated preva-
lence of RHD, incidence of ARF, and incidence of new
cases of RHD cases across multiple geopolitical regions. In
determining prevalence, the investigators used population-
based data only, extrapolating from cross-sectional studies
conducted in school-aged children and compiling ﬁnal
regional prevalence estimates from studies where preva-
lence was conﬁrmed using echocardiography as opposed to
auscultation. This study found an overall global burden of
471,000 annual cases of ARF, with the incidence of ARF in
children ages 5 to 15 years ranging from 10 cases per
100,000 in industrialized countries to 374 cases per
100,000 in the Paciﬁc region. The overall burden of RHD
was estimated to be 15.6 million prevalent cases with
282,000 new cases and over 233,000 deaths per year. As
the investigators noted in their publication [4], there are
some important caveats in these estimates relating to the
number of available studies, extrapolations made to reach
all-ages estimates and global mortality estimates, and the
signiﬁcance of echocardiographic detection of RHD in
screening studies. All of these issues are discussed here.189
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Three groups subsequently reviewed the global burden of
ARF and RHD; 2 reports were published in 2011 [2,3], and
a third, as part of the Global Burden of Disease 2010 Study,
was published in 2013 [7].
The ﬁrst study added several new datasets, used a
clearly deﬁned systematic review design, included only
studies in which RHD was diagnosed by echocardiogram
[8], and incorporated vital registration data from the World
Health Organization. Mortality rates were calculated using
the most recent population data in the World Health
Organization database, but countries were included only if
completeness of death reporting was more than 90% of the
total deaths occurring in the country. The study concluded
that there is considerable global variation in ARF incidence
and RHD prevalence with the sub-Saharan African and
Asian-Paciﬁc regions identiﬁed as high disease burden
areas. The study noted several limitations including that
data were unavailable from several parts of the world and
that there were very few data regarding RHD mortality. Key
estimates that were not addressed included the burden
caused by the distal sequelae of RHD (congestive cardiac
failure, infective endocarditis, atrial ﬁbrillation, and stroke),
average duration of disability for incident cases, average
duration to death, and relative risk of patients with RHD
dying from all causes relative to those without RHD.
The second study [3] observed that the overall global
prevalence of RHD appears to be increasing while the inci-
dence of ARF is decreasing in many parts of the world,
including inAfrica. The investigators explained this apparent
discrepancy by reporting bias; that is, that systematic
reporting of ARF in many countries has decreased at the
same time that RHD case ascertainment has increased
because of RHD screening studies. The investigators also
suggested that longer survival of patients with RHD may
have contributed to this discrepancy, but there are few data
to support this assertion [9].
The recently published Global Burden of Disease Study
reports that the number of years lived with disability due to
RHD was estimated in 2010 at 1,430 (944 to 2,067)
worldwide, a ﬁgure that represents up to one-fourth of all
neoplasms [10]. Lozano et al. [11] reported 345,100 deaths
due to RHD in 2010, which represents a 25.4% reduction
from 1990, with ages-standardized death rate of 5.2 per
100,000, which was a 53.1% reduction from 1990. These
ﬁgures should be viewedwith caution, however, particularly
because the modeling method adopted in the analysis of the
data uses a different age-related proﬁle of RHD than that used
in the previous reviews of the global burden of the disease.
Further analysis of these data is currently underway
(J. Carapetis, personal communication, June, 2013).Uncertainty around estimates of rheumatic heart
disease: inadequate data
The 2005 study included 57 studies of RHD from multiple
geographic regions of the world [4]. Even though thepublication of these data ﬁlled an important gap in the
literature, there were some signiﬁcant limitations. The
major limitation was the poor-quality data from some of
the most affected regions, especially relating to mortality,
with only a single publication available from some regions
of importance, including Eastern Europe and China.
Because of the paucity of data, prevalence ﬁgures from a
small number of studies in a limited number of countries
were extrapolated to whole regions, thereby ignoring the
considerable differences in disease burden that are likely to
exist between countries and, indeed, between states and
districts within many of the larger countries. For example,
many prevalence studies of RHD cited in this study were
conducted in urban and peri-urban populations, although
it is known that the prevalence of RHD is often higher in
rural areas [12,13].
Uncertainty around estimate of rheumatic heart
disease: extrapolation of data
Screening for RHD at a population level has been most
consistently carried out in children ages 5 to 15 years. RHD
is a cumulative disease such that there are more people
over 15 years old with the disease than under 15 years. To
extrapolate to all-ages estimates of RHD, the investigators
of both the 2005 and the ﬁrst of the 2011 studies used a
multiplication factor of between 5.5 and 7.2 on the basis of
published data from 2 studies [14,15]. Although care was
taken to err on the side of underestimation rather than
overestimation, these extrapolated ﬁgures are clearly sub-
ject to error. The burden of RHD mortality was derived
from the overall prevalence of RHD by applying an annual
case-fatality rate per year of 1.5%; this extrapolation was
based upon limited data, including data from industrialized
countries where quality of care is higher. Therefore, the
annual number of global deaths due to RHD estimated in
these studies is likely to be an underestimate of the true
situation in endemic regions; for example, in Pakistan and
Ethiopia, the mortality rate has been reported as high as
6.8% and 12.1%, respectively [2,16]. Ideally local mortality
rates should be applied to local RHD prevalence ﬁgures to
compile overall mortality.
Uncertainty around estimates: progression of
echocardiographic changes detected as part of
screening
The methodology used for detecting RHD in screening
studies of asymptomatic children has progressively changed
over the past 2 decades from auscultation for a murmur, to
auscultation with second-line echocardiographic conﬁrma-
tion of suspected cases, to ﬁrst-line echocardiography
without auscultation. The ﬁrst study that used echocardio-
graphic diagnosis as ﬁrst-line screening for RHD in asymp-
tomatic school children was published in 1996 [17]. This
study went largely unrecognized until just over 10 years
later, when a new era of prevalence studies in asymptomatic
school children in affected countries commenced [18e24].GLOBAL HEART, VOL. 8, NO. 3, 2013
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These studies focused the world’s attention on the seemingly
submerged iceberg of asymptomatic RHD because the
number of cases detected by echocardiography compared
with those detected by auscultation differed by a factor of up
to 10 [18]. The specter of subclinical carditis in the context of
ARF is well recognized [25,26], and the concept of insti-
tuting early prophylaxis in asymptomatic RHD in high
prevalence areas to retard progress to RHD is very attractive.
However, application of prevalence ﬁgures determined by
studies that used ﬁrst-line echocardiography diagnosis to
regional estimates of RHD leads to a considerably higher
burden of disease than has previously been estimated [23].
There are several critical issues regarding echocardiographic
diagnosis of RHD in asymptomatic patients, and these are
discussed in detail herein.
WHAT IS SUBCLINICAL RHEUMATIC HEART
DISEASE?
Subclinical RHD has not been formally deﬁned in the
literature, although subclinical carditis has been deﬁned as
part of the presentation of ARF. A patient with subclinical
RHD is asymptomatic, has no clinically detectable patho-
logic murmur, but has ﬁndings of RHD on echocardiogram
(Table 1). There is a spectrum of ﬁndings of RHD on
echocardiogram suggestive of subclinical RHD. The estab-
lishment of World Heart Federation standardized criteria
for the diagnosis of RHD on echocardiogram has been an
extremely important advance and has helped to reﬁne these
ﬁndings into “deﬁnite” RHD and “borderline” RHD on the
basis of available evidence and expert consensus opinion
(Table 2) [27].
However, there remain a number of troubling aspects
to subclinical ﬁndings suggestive of RHD on echocardio-
gram, with few data available to guide both the clinician
deciding upon a course of action for an individual patient
and the epidemiologist trying to determine whether pa-
tients with these subclinical ﬁndings should be added to
the total number of RHD cases. This is especially true of
borderline RHD; it has been unclear whether borderline
RHD is at the very mild end of the spectrum of RHD, or
whether it is simply a normal physiologic variant.
Does subclinical carditis occur in rheumatic fever?
The Jones criteria for the diagnosis of ARF were last
updated in 1992, and at that time, echocardiographicTABLE 1. Spectrum of rheumatic heart disease and correlation to ec
Clinical
Symptoms
Symptomatic rheumatic heart disease Yes
Asymptomatic clinical rheumatic heart
disease
No Y
Asymptomatic subclinical rheumatic heart
disease
No
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manifestation of carditis [28]. However, many clinicians
use echocardiography in both the assessment and diagnosis
of carditis in patients with ARF. In Australia and New
Zealand, echocardiographic ﬁndings without clinical signs
(that is, subclinical carditis) is accepted as fulﬁlling the
criteria for carditis [29].
Figueroa et al. [30] were the ﬁrst to examine the natural
history of subclinical carditis in the context of ARF. Of 25
patients with carditis at presentation of ARF, 15 had clinical
and echocardiographic evidence of carditis and 10 had
echocardiographic evidence only; in both groups, valvular
changes persisted in over 40% of cases at 1- and 5-year
follow-up. Three further studies focused speciﬁcally on the
long-term follow-up and evaluation of subclinical carditis
[26,31,32]. Taken together, the available data suggest that
subclinical carditis occurs in 15% to 20%of cases of ARF and
that 30% to 50% of patients with subclinical carditis develop
RHD [33]. Karaaslan et al. [32] concluded that subclinical
lesions represent true, albeit mild, carditis and that patients
require secondary prophylaxis and follow-up. They also
concluded that the use of strict criteria for the echocardio-
graphic diagnosis of carditis could increase the sensitivity for
the diagnosis of ARF, especially in patients with atypical
disease such as monoarthritis without leading to over-
diagnosis. Stricter criteria have subsequently been developed
[25,34,35].
What is known about the progression of subclinical
rheumatic heart disease over time?
There have been 3 studies in the modern era that have
reported on short-term progress of subclinical RHD in
asymptomatic populations [22,23,36,37]. The ﬁrst study
assessed the outcome of mitral regurgitation found at
screening after 2 years of follow-up. The investigators re-
ported that signiﬁcant mitral regurgitation coexisting with
morphological abnormalities was more likely to persist on
follow-up examination. Of 15 children with both regurgi-
tation and morphologic changes, 1 child had worsening of
echocardiographic ﬁndings, 10 had persisting changes, and
4 children had regression of regurgitation, although they
still had residual morphological changes. In contrast, 39%
of screened children with isolated regurgitation without
morphologic changes were shown on follow-up to have
completely regressed with no residual pathologicalhocardiographic ﬁndings
Clinical
Signs Echocardiographic Findings
Yes Moderate to severe deﬁnite rheumatic heart
disease
es (murmur) Mild (to moderate) deﬁnite rheumatic heart
disease
No Mild deﬁnite rheumatic heart disease or
borderline rheumatic heart disease
191
TABLE 2. Summarized 2012 World Heart Federation criteria for the echocardiographic diagnosis of rheumatic heart disease [27]
Echocardiographic Criteria for Individuals Aged 20 Years
Deﬁnite RHD (A, B, C, or D)
A. Pathological MR and at least 2 morphological features of RHD of the MV
B. MS mean gradient 4 mm Hg
C. Pathological AR and at least 2 morphological features of RHD of the AV
D. Borderline disease of both the AV and the MV
Borderline RHD (A, B, or C)
A. At least 2 morphological features of RHD of the MV without pathological MR or MS
B. Pathological MR
C. Pathological AR
Criteria for Pathological Regurgitation
Pathological mitral regurgitation Pathological aortic regurgitation
(All 4 Doppler echocardiographic criteria must be met)
Seen in 2 views Seen in 2 views
In at least 1 view, jet length 2 cm In at least 1 view, jet length 1 cm
Velocity 3 m/s for 1 complete envelope Velocity 3 m/s in early diastole
Pan-systolic jet in at least 1 envelope Pan-diastolic jet in at least 1 envelope
Morphological Features of RHD
Features in MV Features in AV
AMVL thickening 3 mm (age-speciﬁc) Irregular or focal thickening
Chordal thickening Coaptation defect
Restricted leaﬂet motion Restricted leaﬂet motion
Excessive leaﬂet tip motion during systole Prolapse
These have been summarized for the purposes of this review. Please see the full referenced article for important explanatory notes and caveats.
AMVL, anterior mitral valve leaﬂet; AR, aortic regurgitation; AV, aortic valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; RHD,
rheumatic heart disease. Adapted, with permission, from Remenyi et al. [27].
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192regurgitation on echocardiography, and none of these
children were found to have worsening of echocardio-
graphic ﬁndings. On short- to medium-term follow-up
(range 3 to 27 months) in the RHEUMATIC (Rheumatic
Heart Echo Utilisation and Monitoring Actuarial Trends in
Indian Children) study [22], the severity of “subclinical
RHD” was nonprogressive in 68% of children, whereas it
worsened in 4% and regressed in 28%. In a follow-up
study of patients detected with RHD by echocardio-
graphic screening in Nicaragua, 9% of the cohort devel-
oped progression of anatomic changes or worsening mitral
regurgitation over the 4-to-12-month follow-up period
[23]. These studies represent the ﬁrst indication that the
natural history of subclinical lesions in asymptomatic
populations follows that seen in ARF and that deﬁnite
disease does have the potential to worsen.
Supporting the echocardiographic follow-up studies,
clinical studies prior to the echocardiographic era also
showed similar results. In a 4- year follow-up study of
patients with abnormalities detected on auscultation,
patients with short systolic murmurs and nonejection clicks
(most likely corresponding to borderline disease using
today’s deﬁnitions) weremost likely to regress or persist with
very few progressing to overt RHD [38]. In comparison,
patients with bona ﬁde murmurs were found to have
persistent clinical ﬁndings with a small percentage requiring
tertiary follow-up or intervention [39].Does the prevalence of subclinical rheumatic heart
disease differ between endemic and nonendemic
populations?
An alternate epidemiologic method to determine the true
meaning of subclinical ﬁndings of RHD on echocardiogram
is to assess the prevalence of these ﬁndings in endemic and
nonendemic populations. Two studies have made these
direct comparisons; however, data are not yet available
from either study.
How can the meaning of subclinical rheumatic
heart disease best be determined?
Well-designed, longitudinal, observational studies of pa-
tients identiﬁed with subclinical disease will be important in
expanding our understanding of subclinical RHD. A po-
tential confounder in these studies that will need to be
accounted for in the analysis will be secondary prophylaxis;
that is, if patients are started on secondary prophylaxis, this
could modify their disease progression and eventual
outcome. Comparison of the progression of echocardio-
graphic changes and incidence of ARF in patients with
subclinical RHD to people with normal echocardiogram
ﬁndings will complement these follow-up studies. Finally, a
randomized controlled study of a known effective inter-
vention for RHD (i.e., antibiotic prophylaxis) in patientswith
subclinical RHD may provide the ultimate evidence forGLOBAL HEART, VOL. 8, NO. 3, 2013
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deﬁning the meaning of subclinical RHD; however, this
study would require clinical equipoise, which may not exist
if the results from the simpler observational studies are
unequivocal.How should rheumatic heart disease prevalence
determined by echocardiographic screening be
incorporated into global burden of disease
estimates? Toward a new model of rheumatic
heart disease
Theuse of echocardiography as a screening tool no doubt has
a major role to play in disease control as well as for advocacy
and awareness of RHD [40]. However, using these numbers
in computing overall disease ﬁgures carries the potential for
an inaccurate description of the burden of disease.
It is perhaps time to change the way that we think
about RHD and attempt to describe the disease burden
with greater subtlety that takes into account our increasing
understanding of the disease. Such a revised model might
include an assessment of RHD burden in 2 categories: 1)
symptomatic disease, which could also be called active
disease; and 2) asymptomatic disease, which could also be
called latent disease (Fig. 1). This approach has some
similarities (but also obvious differences) to the model of
disease applied to other latent diseases including infection
with Mycobacterium tuberculosis.BURDEN OF DISEASE ESTIMATES: THE VALUE OF
ESTIMATING THE BURDEN OF RHEUMATIC HEART
DISEASE CAUSING SYMPTOMATIC DISEASE
As noted, the prevalence of RHD detected in screening
studies largely indicates the burden of asymptomatic RHD,
as well as some cases of symptomatic disease that have
previously been undetected. There are a number of otherFIGURE 1. A new model for assessing and reporting the
burden of rheumatic heart disease that incorporates
asymptomatic and symptomatic disease. *Sequelae
include atrial ﬁbrillation, infective endocarditis, and
stroke. RHD, rheumatic heart disease.
GLOBAL HEART, VOL. 8, NO. 3, 2013
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regarding symptomatic patients; these include RHD regis-
try data, hospital admission data including RHD in preg-
nant women, and RHD surgical data. We believe that these
data have been underestimated and an assessment of the
link between asymptomatic and symptomatic disease has
been neglected.
The clinical characterization of cases on RHD registers
and the incidence of cases presenting to the hospital have
been described in very few centers. A study arising from a
clinical registry in Soweto, South Africa, estimated the
annual incidence of new cases of RHD in the region to be
23.5 cases per 100,000 people over 14 years of age [41]. This
study highlighted the severity of disease in patients pre-
senting for the ﬁrst time with symptomatic RHD; the ma-
jority of patients presented with impaired systolic function,
elevated right ventricular systolic pressure>35 mm Hg and
atrial ﬁbrillation, and surgery was necessary in 22%. The
study also highlighted the relevance of the complications of
RHD; 26% were admitted within 30 months of initial diag-
nosis for suspected infective endocarditis.
RHD as a cause of fetal and maternal morbidity and
mortality has been underestimated. In a study of pregnant
womenwith RHD in Senegal, thematernalmortality ratewas
34%, peaking at 54% forwomenwithmitral stenosis [42]. In
South Africa, 0.6% of pregnant women have pre-existing
cardiac abnormalities, with RHD being the commonest
cardiac problem [43]. In the Paciﬁc, RHD is a leading cause
ofmaternalmortality, and in a study fromFiji, the prevalence
of RHD in pregnant women was 0.2% [44].
Signiﬁcant challenges exist in the provision of cardiac
surgery regions where RHD is endemic [45e47]. Cardiac
surgery is expensive and a lack of infrastructure, human
resources, and equipment makes it almost impossible to
provide timely and appropriate surgery. The collaboration
between nongovernmental agencies as well as humanitarian
missions has been essential in providing a cardiac service in
many parts of the developing world [48]. Surgery for RHD is
challenging, with the complication of prosthetic valves,
anticoagulation, and failed repairs, being an ever-present
issue. Results differ among units and relate largely to expe-
rience, the time of presentation, timing of surgery, and
presence of comorbidities [49,50]. Comprehensive data
regarding all aspects of cardiac surgery for RHD, including
needs, costs, outcomes, and complications are urgently
needed, especially for countries with a high burden of RHD
attempting to establish cardiac surgical programs [51].Rheumatic fever incidence, subclinical rheumatic
heart disease, and symptomatic rheumatic heart
disease: Do the numbers add up?
There are very few populations worldwide that have been
sufﬁciently studied to allow modeling and linking of RHD
prevalence (deﬁnite and borderline), ARF incidence,
RHD incidence (symptomatic cases), RHD surgery, and
RHD mortality. A modeling exercise such as this could193
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borderline RHD, as well as the ability to use a single marker
of disease burden (such as the number of deﬁnite cases
detected through screening programs) to extrapolate to
multiple downstream measures of disease. It is important
to note that the number of deﬁnite cases of RHD has been
shown to remain relatively consistent in recent studies in
multiple diverse populations at a prevalence of 3 to 8 per
1,000. Populations in the Paciﬁc (Australia, New Zealand,
and Fiji) as well as in South Africa are currently in the best
position with high-quality data to allow this type of
modeling to be performed, although many other countries
are developing improved disease surveillance systems.FUTURE EFFORTS TO BETTER DEFINE THE TRUE
BURDEN OF DISEASE DUE TO RHEUMATIC FEVER
AND RHEUMATIC HEART DISEASE
Moving forward, it will be critical to generate high-quality
and comprehensive data regarding all aspects of the
burden of ARF and RHD to better inform national, regional,
and global control strategies [52]. Although there are
increasing data on RHDprevalence from screening studies in
school-aged children, there is considerable value in non-
prevalence data. New studies are underway in several high-
prevalence sentinel areas in diverse geographic locations to
address the need for contemporary data [53]. Particular
emphasis must be given to comprehensive, prospective
cohort studies of long-term outcome particularly related to
progression of disease to the distal sequelae of RHD, such as
stroke, atrialﬁbrillation, and infective endocarditis, aswell as
duration of disability, mortality rates, and economic impact.
Medium- and long-termdata that chart the course of patients
with subclinical disease detected by echocardiography is
necessary to delineate the natural history of subclinical car-
ditis and to inform future control strategies. These data will
provide vital information in order to advocate even more
strongly for directed funding and public health interventions
to control ARF and RHD.REFERENCES
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